RecruitingPhase 1NCT07431398

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

A Phase 1, Open-Label Study to Assess Pharmacokinetics After Single Doses of Pociredir in Participants With Sickle Cell Disease

Sponsor

Fulcrum Therapeutics

Enrollment

24 participants

Start Date

Dec 13, 2025

Study Type

INTERVENTIONAL

Conditions

Sickle Cell Disease

Summary

This clinical trial is a study to evaluate the pharmacokinetics of the tablet formulation Pociredir in fasted and fed state participants with Sickle Cell Disease (SCD).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Pociredir for people with sickle cell disease. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPociredir

Pociredir tablet formulation

Locations(6)

Advanced Pharma - Miami

Miami, Florida, United States

Omega Research Group

Orlando, Florida, United States

Sonar Clinical Research

Riverdale, Georgia, United States

Neuro-Behavioral Clinical Research

North Canton, Ohio, United States

University of Texas Health Science Center Houston

Houston, Texas, United States

Worldwide Clinical Trials

San Antonio, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07431398

Related Trials

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT0643908232 locations

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT065466709 locations